Oncology

A South Korean startup therapeutics company Nunaps has successfully raised USD 4.2 Million around 5 billion won in a Series A round.  The investment was made by the K Partners, KTB Network, and K2 Investment Partners. Nunaps is digital therapeutics and is planning to use the funds to build its digital therapeutics platform to diagnose neurological disorders.  Nunap Vision is a SaMD (Software as a Medical Device) which utilises HMD VR. Its clinical efficacy has already been demonstrated, however, the pivotal multi-centre, double-blind, randomised, and a placebo-controlled clinical trial will further validate the product. The product is designed to provide pe...